Viking Therapeutics, Inc.
0VQA.L
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.49B
Close$
Share Statistics
| Market cap | $3.49 Billion |
|---|---|
| Enterprise Value | $3.37 Billion |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | -130.98% |
|---|---|
| Return on Assets | -102.47% |
| Return on Invested Capital | -134.74% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -6.07 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Viking Therapeutics Inc
53 employees
CEO: Brian Lian Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to developing innovative therapies for metabolic and endocrine disorders. Its flagship product candidate, VK2809, is an orally administered, tissue-...